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The Cys6’ mutant of the TnlO-encoded metal-tetracycline/H’ antiporter is the only one which is inactivated by sulfhydryl reagents among the Cys 
mutants of the putative loop,~, region [Yamaguchi, A. et al. (1992) J. Biol. Chem. 267, 19155519162]. The tetracycline transport activity of the 
CYSTS mutant was completely abolished by N-ethylmaleimide; however, methyl methanethiosulfonate only abolished 45% of the activity, even in 
the presence of an excess of the reagent. Since N-ethylmaleimide did not further inactivate the methyl methanethiosulfonate-treated antiporter, 
it is clear that the modified antiporter molecule with a small substituent, a thiomethyl group, had significant but lower activity than the unmodified 
antiporter. The binding of [“‘C]N-ethylmaleimide to the CYSTS mutant was inhibited in the predsence of tetracycline. These findings indicate that 
position 65 is close to the site of the interaction with the substrate and the modification of the side chain at this position caused steric hindrance 
as to substrate translocation. 
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1. INTRODUCTION 
The transposon Tn 1 O-encoded metal-tetracycline/H+ 
antiporter (TnlO-TetA) is one of the class B tetracycline 
resistance determinants and confers the highest resis- 
tance among the bacterial tetracycline resistance deter- 
minants [l]. The sequences of the class A, B, and C TetA 
proteins are highly homologous [2], and, on the basis of 
the hydropathy profiles, a secondary structure model 
composed of 12 membrane-spanning a-helices and 11 
interhelix loops was proposed [3,4]. The putative struc- 
ture was supported by the results of protease digestion 
[3] and antibody binding [3,5], and the finding that fu- 
sions of the TetA protein to alkaline phosphatase [6] 
have both their N- and C-termini on the cytoplasmic 
side [3,5,6]. 
The putative loop,_, of TnlO-TetA, which was as- 
sumed to be located on the cytoplasmic surface and to 
be composed of 10 residues [4], is especially homologous 
not only in the class A, B, and C TetA proteins [2], but 
also in the bacterial drug eflhtx proteins [7,8] and other 
secondary transporters, including sugar/H’ symporters 
and glucose transporters [9]. Loop,_, was originally pre- 
dicted to be a tetracycline binding site [lo]. In a previous 
paper, we showed that the negative charge of Aspa at 
the middle of this loop is essential for the tetracycline 
transport function [l 11. Since the substrate transported 
is a monocationic chelation complex [12], it is possible 
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that Asp66 is the residue that first interacts with the 
substrate. SeP itself is not important for the transport 
function, yet the CYSTS mutant of the TnlO-TetA protein 
was completely inactivated by N-ethylmaleimide 
(NEM) [ll]. The wild type TetA protein has only one 
cysteine residue, at position 377, but its activity is not 
affected by NEM [l 11. Surprisingly, the CY$‘~ mutant 
was the only Cys mutant of which the transport activity 
was abolished by NEM among the Cys mutants of the 
loop,_, region [4]. 
In this work, we found that the degree of inactivation 
of the CYSTS mutant by sulfhydryl reagents depends on 
the volume of the substituent, and the modification of 
Cys@ by [14C]NEM was inhibited by the presence of 
excess tetracycline. These observations supported the 
hypothesis that Asp& is the residue that first interacts 
with a monocationic substrate and the inactivation of 
the CYSTS mutant by sulfhydryl reagents was due to the 
neighboring bulky substituent exerting steric hindrance 
on the substrate-Asp@ interaction. 
2. MATERIALS AND METHODS 
2. I. Materials 
N-Ethyl[2,3-‘4C]maleimide (333 MBq/mmol) and [7-‘H(N)]tetracy- 
cline (23.7 GBq/mmol) were purchased from Amersham and DuPont- 
New England Nuclear, respectively. Methyl methanethiosulfonate 
was purchased from Aldrich Chemical Co. All other materials were 
of reagent grade and obtained from commercial sources. 
2.2. Plasmids 
pLGT2 is a low-copy-number plasmid containing the wild type 
TnlO-terA and rerR genes [13]. pLGS65C is a derivative of pLGT2 
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encoding the CY$‘~ mutant tetA gene which was constructed by site- 
directed mutagenesis [ll]. 
2.3. Preparation of inverted membrane vesicles and assay of transport 
Inverted membrane vesicles were prepared from Escherichia coli 
W3104 [14] cells carrying pLGT2 or pLGS65C as described previously 
[15]. [3H]Tetracycline uptake by inverted membrane vesicles was as- 
sayed as described previously [12] in the presence of 50 ,uM CoCI,, 10 
,uM [‘HItetracycline and 2.5 mM NADH in 50 mM MOPS-KOH 
buffer (pH 7.0) containing 0.1 M KC1 unless otherwise stated. [3H]Tet- 
racycline was diluted 5 times with unlabeled tetracycline just before 
use. 
2.4. Assaying of binding of [“C]N-ethylmaleimide to TetA proteins 
Inverted membrane vesicles (0.5 mg protein) were incubated in 100 
~1 of 50 mM MOPSKOH buffer (pH 7.0) containing 0.1 M KCI, 5 
mM MgSO, and 0.5 mM [14C]NEM at 30°C for 1 min in the presence 
or absence of 1 mM tetracycline. Immediately after the incubation, the 
vesicles were diluted with 800 ~1 of 50 mM MOPS-KOH buffer (pH 
7.0) containing 0.1 M KCI and excess unlabeled NEM (10 mM) to stop 
the binding. Then the vesicles were precipitated by ultracentrifugation 
at 200,000 x g for 30 min at 4°C with a Beckman ultracentrifuge, 
Optima TL. The resultant precipitate was solubilized in 200 ,uI of 10 
mM sodium phosphate buffer (pH 7.4) containing 0.1 M NaCl, 1% 
Triton X-100, 0.1% SDS and 5 mM unlabeled NEM by brief sonica- 
tion with a Branson bath sonifier. Insoluble substances were removed 
by ultracentrifugation at200,000 x g for 30 min at 4°C. The resultant 
supernatant was mixed with 15 ,uI of anti-TetA-carboxyl-terminal n- 
tiserum [5] in an Eppendorf tube, followed by incubation at room 
temperature for 1 h with shaking. Then 120~1 of a Pansorbin S. aureus 
cell suspension (Carbiochem) [16] was added to the mixture and the 
incubation was continued for a further 1 h. The immunoprecipitate 
was collected by centrifugation at 1,000 x g for 10 min at room tem- 
perature, and then washed twice with 10 mM sodium phosphate buffer 
(pH 7.4) containing 0.1 M NaCI, 1% Triton X-100 and 0.1% SDS. SDS 
gel electrophoresis of the precipitate was performed and the radioac- 
tive band was visualized by autoradiography. 
3. RESULTS AND DISCUSSION 
3.1. Inactivation of the Cys6’ mutant TetA protein by 
N-ethylmaleimide and methyl methanethiosulfonate 
Inverted membrane vesicles were prepared from E. 
coli W3104 cells carrying pLGT2 or pLGS65C. Ten ,ul 
of the vesicle suspension (35 ,ug protein) in 50 mM 
MOPS-KOH buffer (pH 7.0) containing 0.1 M KC1 was 
mixed with 0.5 ,ul of various concentrations of NEM or 
methyl methanethiosulfonate (MMTS), followed by in- 
cubation for 29 min at 30°C. Then, 0.5 ~1 of 250 mM 
NADH was added and the incubation was continued 
for a further 1 min. Tetracycline uptake was started by 
the addition of 40 ~1 of an assay mixture comprising 
12.5 PM [3H]tetracycline (final cont. 10 PM), 62.5 PM 
CoCl, (final cont. 50 PM) and 0.1 M KC1 in 50 mM 
MOPS-KOH buffer (pH 7.0). After 30 s incubation at 
3O“C, 2 ml of a wash buffer comprising 0.15 M LiCl in 
5 mM MOPS-KOH (pH 7.0) was added, and then the 
mixture was rapidly filtered through a nitrocellulose 
filter (24 mm diameter; pore size, 0.45 pm). The filter 
was washed twice with 2 ml of the wash buffer and then 
the radioactivity on it was determined with a liquid 
scintillation counter. 
Active transport activity was calculated by subtract- 
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Fig. 1. Inactivation of tetracycline transport activity of Cys6j mutant 
inverted membrane vesicles by Wethylmaleimide and methyl methan- 
ethiosulfonate. The inactivation and the transport assay were per- 
formed as described in section 2. Open circles and open squares repre- 
sent the residual activity after treatment with NEM and MMTS for 
30 min, respectively. Closed circles represent the activity after sequen- 
tial treatment with 2 mM MMTS for 5 min and then the indicated 
concentrations of NEM for 30 min. 
ing the initial 30 s uptake of [3H]tetracycline in the 
absence of NADH from that in the presence of NADH. 
The residual activity, expressed as a percentage, was 
determined by dividing the residual active transport ac- 
tivity by the activity of the vesicles incubated in the 
absence of a sulfhydryl reagent. As shown in Fig. 1, 1 
mM NEM caused complete inactivation of the CYSTS 
mutant vesicles, while the wild type vesicles were unaf- 
fected by 5 mM NEM (data not shown). On the other 
hand, only 45% of the activity of the Cys6’ mutant 
vesicles was abolished by excess MMTS (5 mM) (Fig. 
1). This incomplete inactivation is not due to incomplete 
modification of the CY.?~ mutant TetA protein by 
MMTS, because when the vesicles were at first incu- 
bated with 2 mM MMTS for 5 min followed by incuba- 
tion with various concentrations of NEM for 30 min, 
the degree of the inactivation did not increase any fur- 
ther than the level of inactivation with MMTS alone. 
Thus, it is clear that all of the CY&‘~ mutant TetA mol- 
ecules were modified with a thiomethyl substituent after 
5 min incubation with MMTS and each thiomethyl 
modified TetA molecule is about 55% active compared 
with an unmodified one. 
In a previous paper [l 11, we reported that the degree 
of inactivation of the CYSTS mutant by MMTS was 
about 60%. In the present work, the degree of inactiva- 
tion was less than that in the previous work. One reason 
for this is that the level of inactivation was overesti- 
mated in the previous work because the residual activity 
was normalized as to the activity before incubation. The 
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Fig. 2. Binding of [‘%jNEM to TetA proteins. Vesicles containing 
wild type TetA (lanes 1 and 2) or CyP5 mutant TetA (lanes 3 and 4) 
were incubated with [‘%]NEM in the absence (lanes 1 and 3) or 
presence (lanes 2 and 4) of 1 mM tetracycline. After solubihzation of 
the vesicles, the TetA proteins were immunoprecipitated as described 
in section 2, followed by SDS polyacrylamide gel electrophoresis. 
(A) Coomassie brilliant blue staining. (B) Autoradiography. 
incubation of the vesicles without a sullhydryl reagent 
caused a little decrease in the activity. The residual ac- 
tivity in the present work was normalized as to the 
activity of vesicles incubated for the same period in the 
absence of a reagent. However, such normalization 
could not explain all the discrepancy between the re- 
sults. Anyway, the degree of inactivation in the present 
work was highly reproducible and the discrepancy does 
not change the conclusion. 
Sequential treatment with MMTS and NEM solved 
the outstanding problem in the previous work of 
whether the incomplete inactivation by MMTS was due 
to incomplete modification of the CYSTS mutant by 
MMTS or because each molecule of the thiomethyl 
modified Cys6’ TetA protein had lower activity than the 
unmodified one. The latter is the case. This suggests that 
the inactivation is due to simple steric hindrance with- 
out protein denaturation. 
3.2. Inhibition of [‘“C]N-ethylmaleimide binding to the 
CysG5 mutant TetA by tetracycline 
As shown in Fig. 2, when the Cys6’ mutant vesicles 
were incubated with 0.5 mM [14C]NEM for 1 min in the 
absence of tetracycline, a radioactive band correspond- 
ing to the TetA protein was detected on autoradiogra- 
phy. In contrast, the wild type vesicles showed no such 
radioactive band. Thus, it is clear that the radioactive 
band reflects the modification of Cys6’ by [14C]NEM. 
When the CYSTS mutant vesicles were incubated with 0.5 
mM [14C]NEM in the presence of 1 mM tetracycline for 
1 min, the density of the radioactive band decreased 
substantially (Fig. 2). Since there was no significant 
difference in the amounts of the TetA proteins visual- 
ized on Coomassie brilliant blue staining, the decrease 
in the radioactivity indicates the inhibition of NEM 
binding by tetracycline. 
We previously reported that the inactivation of the 
Cys6j mutant by NEM was not affected by the presence 
of 50 ,uM tetracycline [l 11. In that experiment, the con- 
centration of tetracycline was 20-fold lower than that of 
NEM, and the vesicles were treated with NEM for 5 
min, which was 5 times longer than in the present work. 
Therefore, it is concluded that the short-time modifica- 
tion by NEM was inhibited by tetracycline at a concen- 
tration higher than that of NEM. The K,,, value of the 
antiporter as to tetracycline is around 20 PM [11,13]. 
The concentration of tetracycline required for inhibi- 
tion of the NEM modification was considerably higher 
than the K, value. Thus, it seems unlikely that the inhi- 
bition reflects the binding of tetracycline to the sub- 
strate recognition site of the antiporter, although it is 
certain that there is some interaction between tetracy- 
cline and a site near CyP leading to competitive inhibi- 
tion of Cys6’ modification by NEM. 
The negative charge of Asp66 is essential for the tetra- 
cycline transport function and is predicted to interact 
with a monocationic divalent-cation-tetracycline chela- 
tion complex [ 111. It is likely that this interaction inhib- 
its the Cys6’ modification by NEM (Fig. 3). These ob- 
servations supported the hypothesis that the loop,_, re- 
gion is a gate at the entrance of the predicted tetracy- 
cline transport channel and that it first interacts with a 
chelation substrate. The substrate recognition site may 
be located in a deep transmembrane channel. 
tetracycline translocation 
channel 
Fig. 3. Model of the steric hindrance of tetracycline translocation on 
modification of Cys6’ with N-ethylmaleimide. The residues constitut- 
ing the putative loop,_, of the Cys? mutant TetA protein are depicted 
as ovals. A positive charge of a divalent cation-tetracycline complex 
is predicted to first interact with the negative charge of Asp%, and then 
the complex molecule enters the putative substrate translocation chan- 
nel. A bulky substituent of CyP may be located at the entrance of the 
channel and thus hinder the tetracycline translocation. 
203 
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